Thomas Wierzba to Clinical Trials as Topic
This is a "connection" page, showing publications Thomas Wierzba has written about Clinical Trials as Topic.
Connection Strength
0.401
-
Barry E, Cassels F, Riddle M, Walker R, Wierzba T. Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Vaccine. 2019 08 07; 37(34):4768-4774.
Score: 0.146
-
Wierzba TF. Implications and measurement of herd protection (indirect effects) for enteric vaccine development. Vaccine. 2019 08 07; 37(34):4775-4777.
Score: 0.146
-
Clemens J, Savarino S, Abu-Elyazeed R, Safwat M, Rao M, Wierzba T, Svennerholm AM, Holmgren J, Frenck R, Park E, Naficy A. Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method. J Infect Dis. 2004 Jun 15; 189(12):2299-307.
Score: 0.051
-
Bourgeois AL, Wierzba TF, Walker RI. Status of vaccine research and development for enterotoxigenic Escherichia coli. Vaccine. 2016 06 03; 34(26):2880-2886.
Score: 0.029
-
Mani S, Wierzba T, Walker RI. Status of vaccine research and development for Shigella. Vaccine. 2016 06 03; 34(26):2887-2894.
Score: 0.029